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Abstract
Interstitial lung disease (ILD) comprises many heterogeneous disease groups, the largest being CTD-
associated and those labelled as idiopathic out of necessity. The mechanisms causing ILD are poorly
understood, but most CTD- and idiopathic-ILD cases can respond to immunosuppression, clearly sug-
gesting a pathological role for inflammation. By contrast, corticosteroid immunosuppression causes harm
without benefit in the feared idiopathic pulmonary fibrosis, suggesting that inflammation plays little patho-
logical role, and where ILD progresses rapidly to lethal outcome even with anti-fibrotic drug use. Given the
treatment response differences apparent between ILD subgroups, and the dangers and costs of cortico-
steroid and anti-fibrotic drug use, respectively, it has become vital in every ILD patient to make an
accurate subgroup diagnosis, to optimize treatment selections. This review discusses why differentiating
CTD- and idiopathic-ILD subgroup cases remains so problematic, and why existing comprehensive CTD-
specific serology would, if generally available, represent an ideal biomarker tool to enhance ILD subgroup
diagnostic accuracy.
Key words: interstitial lung disease, connective tissue disease, antibodies, biomarkers, serology, myositis,
anti-synthetase syndrome.
Rheumatology key messages
. Widely differing interstitial lung disease treatment responses make an accurate subgroup diagnosis essential in
every case.
. CTD-specific autoantibodies represent ideal biomarkers to accurately assign CTD-interstitial lung disease sub-
group diagnoses.
. Existing, comprehensive, CTD-specific serology would, if made routinely available, clearly improve interstitial lung
disease clinical care.
Introduction
The parenchymal tissues of the terminal airways comprise
the alveolar epithelium and basement membrane, the
peri-vascular/peri-lymphatic (i.e. the true) interstitial
space and the capillary basement membrane and epithe-
lium. Damage to any of these tissues could lead to diffuse
parenchymal lung disease, although interstitial lung dis-
ease (ILD) is the preferred UK term [1]. The diffuse paren-
chymal lung disease pattern distinguishes ILD from other
lung pathologies, including those affecting the pleura and
larger airways. If ILD-associated parenchymal injury, and
any associated inflammation, is not arrested to facilitate
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healing, irreversible pulmonary scarring and fibrosis may
follow [2]. It is the combination of parenchymal injury, pri-
mary and/or secondary inflammation, pulmonary fibrosis
and the resulting dyspnoea that physicians recognize
overall as ILD. Impaired gas transfer can occur early, if
inflammatory infiltrations are sufficiently severe, or only
once fibrosis has become substantial, irrespective of
cause. In individual cases the extent of parenchymal
inflammation, relative to that of fibrosis, will depend on
the mechanism causing injury, and also dictate the effect-
iveness of immunosuppressive therapies [3]. Patients ac-
curately diagnosed and treated will normally fare better.
Non-responsive or untreated patients usually progress
from being dyspnoeic on exertion only to being dyspnoeic
even at rest. Fatal outcomes ensue from respiratory fail-
ure, or its cardiac complications [4].
Why the difficulties in diagnosing CTD-
associated ILD?
A representative classification of ILDs is shown in Fig. 1 [5].
Though apparently simple, this classification hides many
potential pitfalls. The two largest ILD groups are the CTD-
associated ILDs (CTD-ILDs) and the idiopathic-ILDs (also
known as the idiopathic interstitial pneumonias, or IIPs).
Both groups have many subgroups. Differentiating between
subgroup cases can prove considerably difficult because
their ILD features can overlap, as can be demonstrated
on lung biopsy material where available, and on high reso-
lution CT (HRCT) scans [6]. Non-specific interstitial pneu-
monia (NSIP) and usual interstitial pneumonia (UIP) patterns
on HRCT can be seen in CTD-ILD and idiopathic-ILD [7].
The NSIP pattern is characterized by ground glass changes
typically present at the periphery and bases of the lungs,
whereas a UIP pattern shows peripherally distributed reticu-
lar and fibrotic changes typically affecting the lung bases
with honeycomb features, and the absence of significant
ground glass changes [8]. The commonest ILD is idiopathic
pulmonary fibrosis (IPF), where scans typically demonstrate
the UIP pattern (IPF and idiopathic UIP are thus inter-
changeable terms). IPF/idiopathic UIP is the most feared
of all ILDs, because it is so relatively common and is asso-
ciated with a 50% mortality within only 3 years of ILD
onset despite all treatments [4] (see later). When a physician
accurately diagnoses a CTD in a patient with NSIP, that
case would obviously be labelled as a CTD-ILD, and the
detected CTD is assumed to be the underlying cause of the
NSIP. If, on the other hand, no CTD signs were detectable,
and no other cause for an NSIP pattern was apparent, that
case would of necessity be assigned an idiopathic-ILD
label, that is, idiopathic NSIP. In each instance, the final
ILD diagnosis will have relied on use of the combined clin-
ical, radiological, serological and (where available) lung
histological features. However, this seemingly logical pro-
cess can break down with CTDs.
This is because ILD may be the presenting sign of a CTD,
that is, where extra-pulmonary CTD features have yet to
appear [911]. ILD thus represents a forme fruste CTD.
Furthermore, CTD symptoms may be present but of only
very subtle character, and so easily missed in a busy respira-
tory clinic. For example, in the anti-synthetase syndrome
the classic CTD features other than ILD (i.e. Raynaud’s
FIG. 1 A classification of ILD into groups and subgroups
The IPF and RA-ILD (UIP) subgroups are formatted left in each box, and made bold, to highlight that these ILDs exhibit
similar fibrotic HRCT patterns (UIP) and are similarly treatment-resistant, with rapid progression to lethal outcomes within
only 35 years of ILD onset. In contrast, and formatted to the right in each box, the other IIP and CTD-ILD subgroups, the
latter including RA-ILD (non-UIP), show varying degrees of cellularity (i.e ground glass) on HRCT, and are usually responsive
to immunosuppression to some extent. IPF: Idiopathic Pulmonary Fibrosis, ILD: Interstitial Lung Disease, UIP: Usual
Interstitial Pneumonia, HRCT: High Resolution Computed Tomography, IIP: Idiopathic Interstitial Pneumonia. (Adapted from
Ryerson CJ, Collard HR. Update on the diagnosis and classification of ILD. Curr Opin Pulm Med 2013;19:4539).
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syndrome, myositis, mechanic’s hands, fever, rash, inflam-
matory arthritis) may be absent or very subtle only [12].
Moreover, if ILD is successfully treated early, the immunosup-
pressive agents used may well preclude the development of
CTD signs other than ILD. Physicians should employ serology
to screen for a CTD in every ILD case, though chest phys-
icians may employ serology less rigorously than would per-
haps be expected of a rheumatologist [13]. False positive
serology and the existence of sero-negative CTDs would
also cause difficulties. A low suspicion for the presence of a
CTD may mean that some CTD-ILD patients never see a
rheumatologist.
The diagnostic limitations of HRCT
HRCT is an important assessment tool to differentiate be-
tween fibrosis and inflammation in ILD patients. Where
clinical history and examination fail to confirm a clear
ILD diagnosis, and no CTD symptoms or signs are appar-
ent, clinicians must then rely on HRCT, if serology is diag-
nostically inadequate or unhelpful. However, HRCT has
poor utility as a stand-alone diagnostic tool. For instance,
HRCT appearances have no proven associations with any
defined disease processes. Also, not only do the same
HRCT patterns occur in different ILD subgroups, but dif-
ferent HRCT patterns can occur in the same disease sub-
group [14]. Furthermore, similar HRCT patterns can be
associated with differential outcomes. For example, the
most common HRCT appearances in SSc are those of
NSIP or UIP, the latter thus mimicking IPF. However, in
contrast to IPF, SSc-ILD patients with UIP can respond to
immunosuppression [1517]. Honeycombing is a
recognized HRCT feature of IPF, but honeycombing can
also occur in myositis-ILD, thus again mimicking IPF, yet
myositis-UIP cases can respond to immunosuppression
[18]. In the absence of comprehensive CTD serology, in-
accurate diagnostic assignments by HRCT will have
occurred previously, and likely will continue to occur.
That fibrotic HRCT changes respond differently in IPF
than in CTD-ILDs with predominantly fibrotic HRCT
changes may reflect differential disease mechanisms.
Such a range and variability of HRCT appearances, clin-
ical associations and treatment responses highlights the
problems of diagnostic uncertainty when CTD-specific
serology is inadequate. In addition, there are the difficul-
ties that HRCT patterns may overlap, and that inter-ob-
server variability of image analysis also occurs [19, 20].
The 2011 American Thoracic Society (ATS)/European
Respiratory Society (ERS) guidelines for the diagnosis
and management of IPF suggested that an accurate ILD
diagnosis is optimally secured by the combination of a
thorough medical history (to detect causative CTDs or oc-
cupational or environmental exposures, etc.), a careful
clinical examination (to detect CTD or granulomatous
signs, etc.), serological screening, an HRCT scan and
lung histology where feasible, though co-morbidities dic-
tate that only a minority of UK cases are sufficiently fit for
lung biopsy [21]. A definite occupational, iatrogenic,
granulomatous, CTD, etc. history and/or detection of clin-
ical signs would likely secure an underlying ILD diagnosis,
and so preclude the need for lung biopsy. However, when
diagnostic doubts remain, final diagnostic decisions are
increasingly made in the UK by expert multidisciplinary
teams in tertiary ILD clinics, with input from pulmonary
clinicians, radiologists, pathologists and increasingly
rheumatologists with an interest in ILD. Tertiary ILD ser-
vice developments have in part been driven by the advent
of newer drugs for IPF, a particularly challenging ILD that
is preceded by little or no inflammation, and that is there-
fore non-responsive to immunosuppression [22, 23].
The diagnostic use of serology in the
absence of ILD-specific biomarkers
A factor that has to date critically limited ILD subgroup
diagnostic capability has been the lack of reliable, ILD-
specific biomarkers. UK physicians, including rheumatolo-
gists, have thus struggled diagnostically with idiopathic
ILD and with CTD-ILD when CTD signs other than ILD
are absent, though this situation is set to improve. IPF
can only be diagnosed once a CTD has been definitively
excluded, but the 2011 and 2013 ATS/ERS guidelines
gave only very limited advice regarding the stringency of
serology required to interrogate for a CTD [21, 24]. Thus,
and even in most tertiary UK ILD clinics, CTD exclusion
continues to rely on routine immunology, that is, immun-
ology testing for rheumatoid factor, anti-CCP antibodies,
ANA and extractable nuclear antigens, the latter usually
limited to anti-Ro/-La/-Jo/-Sm/-RNP/-Scl-70. A recent
ERS/ATS research statement on interstitial pneumonia
with autoimmune features suggests, for the first time,
that classification criteria should contain a serological
domain [25]. This statement suggests use of serology
more extensive than previously advised in any ATS/ERS
guidelines [8, 21, 24], though no details are given regard-
ing how to use this newly advocated serology, or regard-
ing its diagnostic utility [25]. Moreover, for many of the
newer antibody specificities listed in this update, and es-
pecially for some of those associated with myositis, sero-
logical detection systems are unfortunately not currently
available in routine UK clinical practice. Thus, in myositis-
ILD, a growing number of myositis-specific autoantibodies
(MSAs) and myositis-associated autoantibodies (MAAs)
are now detectable (Tables 1 and 2) [26]. MSA/MAAs ac-
curately predict the presence of myositis clinical features,
including the likelihood of developing an associated ILD,
so these antibodies represent surrogate ILD biomarkers,
and hence their inclusion in the most recent ERS/ATS
update [25]. Currently, however, many MSA/MAAs are
only detectable by expensive immunoprecipitation tech-
niques [26], although immunoblot technology for a
number of these antibodies is now available in some
National Health Service hospitals. Even when these are
available, issues of diagnostic accuracy and nomencla-
ture still arise. For instance, in the case of anti-PL-7 and
anti-PL-12, these antibodies often associate with ILD in the
absence of myositis [11, 27], that is, in amyopathic ILD.
Affected patients may not initially or ever exhibit CTD fea-
tures other than their ILD [11, 12]. Reliable detection of an
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ILD-only MSA/MAA here would presumably secure a
CTD-ILD diagnosis, and it could be argued that detected
ILD-only MSA/MAAs could be appropriately renamed as
ILD-specific/associated autoantibodies (i.e. ISA/IAA), or
as CTD-ILD-specific/associated autoantibodies, though
the latter appears somewhat cumbersome, especially
regarding the issue of an acronym. As the intracellular
targets of many MSA/MAAs, and of all eight of the
known anti-synthetases, are cytoplasmic rather than nu-
clear, a negative ANA on routine screening does not of
itself exclude a CTD-ILD diagnosis. However, the staining
patterns observed when ANA screening is undertaken by
indirect immunofluorescence testing on HEp-2 cells will
potentially disclose the presence of a CTD [28, 29]. The
HEp-2 technique is rapid and inexpensive, so if available
its use for screening ILD patients for an underlying CTD is
recommended.
The recently described anti-melanoma differentiation-
associated gene 5 (MDA5) antibody occurs in DM patients
who are clinically amyopathic, but who may suffer a very
aggressive ILD, that is, one proving lethal within months or
only weeks of ILD onset, despite all immunosuppressive
interventions [36]. Anti-MDA5 could thus also be termed
an ISA. Fortunately this antibody and its associated ILD
are rare in the UK [26]. In other CTDs with a potential to
develop ILD with or without myositis, for example, in
mixed CTD, many patients will also possess one or
more MAAs. In SSc there are many SSc-specific antibo-
dies that are also strongly associated with ILD develop-
ment (see Table 2). Thus, MSAs, MAAs and SSc-
associated antibodies should all be regarded as surrogate
biomarkers of ILD, or when appropriate even as ISA/IAAs.
The recent ERS/ATS update recognizes the growing evi-
dence suggesting that serology should be utilized more
readily to enhance CTD-ILD diagnosis. However, this
update also points out that detailed prospective studies
are now required to validate the newly proposed classifi-
cation criteria for interstitial pneumonia with autoimmune
features [25]. In view of the current inadequacies of rou-
tine serology, and given that respiratory physicians may
lack expertise in assessing extra-pulmonary CTD clinical
features, and that these may anyway be absent or of only
subtle degree at ILD onset, it seems likely that at least
some CTD patients with HRCT appearances suggestive
of UIP will be misdiagnosed as IPF. Similarly, some pa-
tients may be assigned an idiopathic-ILD label when they
actually have a CTD-ILD that remains immunologically
undisclosed.
Differential outcomes in CTD-ILDs
In the past, CTD- and idiopathic-ILD patients with similar
HRCT patterns would have been treated with similar im-
munosuppressive regimes, so diagnostic labels then were
therapeutically of lesser importance. However, recent
mechanistic research and clinical trials in IPF have dra-
matically altered the treatment landscape. Making an ac-
curate ILD diagnosis, to differentiate a CTD-ILD from an
idiopathic-ILD, has thus become crucial, as treatments
may differ markedly, and especially between IPF and
most other ILD subgroups. Following the publication of
the PANTHER study, which examined the impact of
TABLE 1 Clinical associations of the known myositis-specific autoantibodies and the likelihood of antibody-positive
patients developing an associated interstitial lung disease
MSA
Prevalence in
myositis (%) Clinical associations Likelihood of developing ILD
Anti-synthetases:
Anti-Jo-1 (histidyl) 1520 Associated with anti-synthetase
syndrome, and characterized
by the presence of:
Myositis (PM or DM)
Arthritis
ILD
Raynaud’s
Fevers
Mechanic’s hands
70% develop ILD [30]
Anti-PL-12 (alanyl) <5 90% develop ILD, myositis
often mild [11]
Anti-PL-7 (threonyl) <5 90% develop ILD, often prior
to myositis [31]
Anti-KS (asparaginyl) <5 90% develop ILD, myositis
rare [32]
Anti-OJ (isoleucyl) <5 Up to 100% develop ILD [33]
Anti-EJ (glycyl) <5 Up to 100% develop ILD [34]
Anti-Zo (phenylalanyl) <1 ILD-associated [35]
Anti-Ha (tyrosyl) <1 No literature
Anti-MDA5 Associated
with clinically
amyopathic DM
Rapidly progressive ILD, espe-
cially in Japanese and Chinese
patients
5070% develop rapidly pro-
gressive ILD in Japanese/
Chinese ethnicity [36, 37],
50% in Caucasian [38]
The following MSAs are rarely if ever associated with likelihood of developing an ILD: anti-Mi-2, anti-NXP2, anti-TIF1-g, anti-
SAE and anti-SRP. ILD: interstitial lung disease; MDA5: melanoma differentiation-associated gene 5; MSA: myositis-specific
autoantibody. (Table adapted from Betteridge ZE et al. Novel autoantibodies and clinical phenotypes in adult and juvenile
myositis. Arthritis Res Ther 2011;13:209.)
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treating IPF patients with high-dose prednisolone co-pre-
scribed with AZA, this immuno-suppressive regime was
deemed contra-indicated because of its thus proven iat-
rogenic dangers [23]. New anti-fibrotic agents such as
pirfenidone and nintedanib are now licensed and available
for use to slow IPF disease progression [5355]. These
agents are, however, considerably expensive, so their
use in England can only be recommended when an IPF
diagnosis is deemed robust, that is, when made in a
designated tertiary ILD centre, and according to the
201113 ATS/ERS guidelines [21, 24].
Most CTD-ILD cases have a capacity to respond to im-
munosuppression. If a degree of fibrosis has already
occurred, suppressing residual inflammation would likely
still act to limit fibrotic progression, thus stabilizing dys-
pnoea and associated disability. Such treatment respon-
siveness supports the notion that in most CTD-ILD cases,
including myositis-ILD, ground glass changes reflect a
suppressible inflammation component [56]. That treat-
ment responses are also seen where fibrotic HRCT
changes predominate in some CTD-ILD cases is poorly
understood. A generic and suppressible inflammatory
component could be assumed in all CTD-ILD cases, yet
treatment outcomes are not always good. For instance,
when RA patients develop an associated ILD (RA-ILD)
with a UIP pattern on HRCT, that is, RA-ILD (UIP), such
cases are notoriously non-responsive to immunosuppres-
sion [57]. RA-ILD (UIP) is associated with a lethal outcome
within only 3 years of ILD onset, thus clearly mimicking IPF
[57, 58]. Moreover, the RA-ILD (UIP) pattern on HRCT is
identical to that of IPF. Therefore, although RA-ILD (UIP) is
much rarer than IPF, it is a diagnosis just as feared as IPF.
No research to date has reported on whether anti-fibrotic
agents have a therapeutic role to play in RA-ILD (UIP).
Some RA-ILD patients may develop organising pneumo-
nia changes on HRCT or NSIP changes on HRCT, rather
than UIP, and these cases do by contrast usually respond
to immunosuppression [57]. Clearly, if a CTD-ILD other
than RA-ILD (UIP) was misdiagnosed as IPF, and immuno-
therapy thus withheld, an opportunity to stabilize disease
progression could be missed. The similarity of outcomes
for IPF and RA-ILD (UIP), the treatment response differ-
ences apparent between IPF and the other idiopathic-
ILDs and between RA-ILD (UIP) and the other CTD-ILDs,
illustrate the degree of heterogeneity that is apparent
within the disease spectrum that ILD represents.
TABLE 2 Clinical associations of various SSc-associated antibodies and myositis-associated antibodies and the like-
lihood of antibody-positive patients developing interstitial lung disease
SSc-associated
antibody or MAA Prevalence of antibody Disease associations Likelihood of developing ILD
Anti-topoisomerase
(Scl70)
30% of SSc patients [39] dcSSc [40] 60% of patients develop ILD
[41]
Anti-Th/To 5% of SSc patients [40] lcSSc [42] 50% of patients develop ILD
[43]
Anti-U3 RNP 8% of patients with SSc [44] Occurs in SSc. Associated with
skeletal muscle involvement
and pulmonary arterial
hypertension [45]
40% of patients have ILD [45]
Anti-U11/U12 RNP 3% of patients with SSc [46] Occurs in SSc 80% of patients develop ILD
which is often severe [46]
Anti-RuvBL1/2 12% of SSc patients [47] Associated with myositis overlap
and diffuse skin thickening [47]
Over 50% of patients will de-
velop ILD [47]
Anti-EIF2B 1% of patients with SSc/
SSc overlap [48]
Associated with SSc/SSc overlap
syndrome
Up to 100% of patients will de-
velop ILD [48]
Anti-PM-Scl Occurs in up to 17% of
patients with overlap myo-
sitis [49], 36% of patients
with SSc [50]
Associated with scleromyositis 50% of patients will develop
ILD [49, 51]
Anti-Ku Occurs in 13% of patients
with overlap myositis [49]
Associated with myositis overlap
syndrome
30% of patients will develop
ILD [49]
Anti-U1 RNP 535% of patients presenting
with SSc or overlap syn-
dromes [50]
Associated with MCTD 35% show HRCT abnormal-
ities associated with ILD,
20% classified as severe
[52]
Anti-Ro-52/60 40% of IIM patients have
anti-Ro-52/60 alongside
their MSA or MAA [51]
Frequently occur with an MSA,
especially with the anti-synthe-
tases, or with various MAAs
40% of patients develop ILD,
however it is unlikely that
these antibodies are respon-
sible for the ILD risk, which is
instead due to the MSA/MAA
detected [51]
The following SSc-associated antibodies are less frequently associated with ILD: anti-centromere antibody and anti-RNA polymerase
III. Table compiled from the cited references. HRCT: high resolution CT; IIM: idiopathic inflammatory myopathy; ILD: interstitial lung
disease; MAA: myositis-associated antibody; MCTD, mixed connective tissue disease; MSA: myositis-specific antibody.
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Academic issues
Given that the 2011 ATS/ERS guidelines for IPF [21] were
constructed without reference to comprehensive serology
to test for MSA or MAA and SSc-associated autoantibo-
dies, a question naturally arises regarding the robustness
of an IPF diagnosis when made without such serology.
Such a stricture may well have blighted previous mechan-
istic IPF research. For instance, in the few research stu-
dies in which relatively comprehensive myositis serology
testing was undertaken in IPF cases, who would by def-
inition have required IPF-consistent HRCT changes for
study inclusion (i.e. UIP, or fibrotic NSIP), the results
demonstrated such serology to be positive in a significant
number of cases [9, 59]. As MSAs have highly significant
HLA associations [60], these results could imply that IPF
also has strong HLA associations, yet genetic studies
using genome-wide association scan technology in IPF
have failed to demonstrate significant HLA associations
[61, 62]. Moreover, many of the MSA-positive cases in
these studies were younger females, an observation
more in keeping with a CTD-ILD rather than an IPF pheno-
type. Some of the MSA-positive IPF cases were presum-
ably myositis-ILD cases, but where the CTD diagnosis had
remained covert until the research myositis serology was
undertaken. In contrast, in a Mexican study, highly signifi-
cant HLA associations were found in IPF [63]. In this study
the IPF diagnoses were based on the 2002 ATS/ERS IIP
diagnostic guidelines, which gave no guidance on use of
serology to interrogate for the presence of a CTD [8]. The
highly significant HLA associations detected in this study,
with odds ratios >10, could again imply that their IPF case
cohort was in fact contaminated by many covert CTD-ILD
cases, such as those with MSA/MAA. The contradictory
nature of these genetic results suggests that, even in a
phenotype as apparently robust as IPF diagnosed strictly
in a specialized ILD clinic setting, case stratification errors
have likely still occurred. To optimize accuracy of case
stratifications to guarantee homogeneous cohorts for
future IPF genetic studies will clearly require modern and
comprehensive serology to be used to definitively exclude
all CTD cases. Amyopathic ILD patients without a rash,
and especially those with an anti-synthetase other than
anti-Jo-1, would clearly cause confusion in any ILD study
where comprehensive serology was not available. If all pa-
tients diagnosed as IPF in a tertiary UK ILD clinic were
interrogated by immunoprecipitation, would a substantial
cohort prove positive for CTD-associated antibodies? If so,
then undertaking comprehensive serology on all incident
ILD cases without obvious CTD signs would seem justifi-
able, at least until this question has been addressed.
Conclusions
The relative paucity of aetiopathological insights so far
gained in ILD reflects the difficulties of accurately assigning
ILD subgroup diagnoses without comprehensive CTD ser-
ology, and that case-stratification errors have likely occurred
in previous research. This may have contributed to the ap-
parent confusion in the literature regarding diagnostic labels,
mechanistic issues and the apparent contradictory nature of
genetic research outputs. These insight deficits also reflect
the rarity of ILD, and that the invasiveness of lung biopsy
procedures has severely hampered investigations of the ILD
organ target. To facilitate accurate future clinical ILD care, so
as to optimizie outcomes, it will be vital that comprehensive
CTD-serotyping becomes standard in routine practice,
though substantial technological developments will be
required to achieve this. Until then, serology by immunopre-
cipitation will continue to be crucial, and especially in the ILD
research setting. Given the extreme rarity of some ILD sub-
groups, and the sample size problems that would arise for
instance during between-subgroup comparative research, it
is essential that multicentre collaborative efforts develop to
recruit the large ILD subgroup cohorts required to facilitate
such research. Such cohorts would make it possible to pro-
spectively correlate ILD clinical phenotypes with serotypes
and HRCT-generated radiological phenotypes for all ILD
subgroups. Examining the validity of HRCT to assign idio-
pathic-ILD subgroup diagnoses would also become pos-
sible. It is feasible that some idiopathic subgroups, such as
idiopathic NSIP and COP, will become smaller or even dis-
appear, as more individual idiopathic-ILD cases are appro-
priately reassigned into CTD-ILD subgroups. Serologically
better defined ILD subgroups will ensure more meaningful
between-subgroup evaluations, for instance in future immu-
nogenetic comparisons. The use of larger, more homoge-
neous subgroup cohorts will clearly facilitate ILD research,
and thus ultimately improve quality of patient care.
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